CMG Pharmaceutical Co., Ltd.
Financials
Valuation Metrics
CMG Pharmaceutical Co., Ltd.'s Market Cap is ₩824B. At end of 2025 it was ₩2752B. Ranked #1396 of 2,421 in KR market (top 58%), #791 of 1,640 on KOSDAQ (top 48%), #150 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 65%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 82.36B KRW | KR#1,396/2,421 Sec#150/231 |
| Revenue | 115.71B KRW | KR#1,333/2,421 Sec#85/231 |
| Net Income | 4.64B KRW | KR#1,241/2,421 Sec#86/231 |
| Total Assets | 320.07B KRW | KR#997/2,421 Sec#63/231 |
| Net Assets | 204.30B KRW | KR#929/2,421 Sec#65/231 |
| Employees | 282 | KR#837/2,421 Sec#70/231 |
| Value | ||
| P/E | 17.75x | KR#1,120/2,421 Sec#68/231 |
| P/B | 0.40x | KR#577/2,421 Sec#19/231 |
| P/S | 0.71x | KR#1,151/2,421 Sec#59/231 |
| FCF Yield | -49.36% | KR—/2,421 Sec—/231 |
| Profitability | ||
| ROE | 2.27% | KR#1,382/2,421 Sec#94/231 |
| ROA | 1.45% | KR#1,319/2,421 Sec#94/231 |
| Op. Margin | -3.14% | KR#1,792/2,421 Sec#121/231 |
| Revenue Growth | 22.15% | KR#514/2,421 Sec#48/231 |
| Financial Health | ||
| Debt Ratio | 56.66% | KR#1,053/2,421 Sec#121/231 |
| Total Debt | 68.50B KRW | KR#875/2,421 Sec#59/231 |
| FCF | -40.65B KRW | KR#2,046/2,421 Sec#201/231 |
| Cash | 11.51B KRW | KR#1,618/2,421 Sec#137/231 |
| Current Ratio | 1.17x | KR#1,528/2,421 Sec#157/231 |
| Performance | ||
| 1Y Return | -70.71% | KR#2,301/2,421 Sec#219/231 |
| 1M Return | -8.85% | KR#2,043/2,421 Sec#170/231 |
| From 52W High | -74.78% | KR#2,285/2,421 Sec#201/231 |
| 1Y MDD | -74.95% | KR#2,178/2,421 Sec#191/231 |
| Trading | ||
| Volume | 338,715 shares | KR#327/2,421 Sec#20/231 |
| Trading Value | 189.4M KRW | KR#1,298/2,421 Sec#131/231 |
| Foreign Own. | 6.48% | KR#681/2,421 Sec#60/231 |
| Per Share | ||
| EPS | 31 KRW | KR#1,522/2,421 Sec#105/231 |
| BPS | 1,379 KRW | KR#2,221/2,421 Sec#195/231 |
Company Info
CMG Pharmaceutical, established in 2001, merged Celltrate Pharm Korea in 2008 and now primarily focuses on the research, development, production, and sales of pharmaceuticals and health functional foods. The company applies oral disintegrating films, leveraging its core STARFILM Technology, to incrementally modified drugs and is expanding its product portfolio into new business sectors like anti-cancer drugs, anti-aging, and ophthalmology. CMG Pharmaceutical is actively pursuing revenue growth and market share expansion through new drug development, facilitated by US FDA product approvals and technology exports. The company is headquartered in Gangnam-gu, Seoul.